These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 21849092)
1. A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. Kawamoto M; Horibe T; Kohno M; Kawakami K BMC Cancer; 2011 Aug; 11():359. PubMed ID: 21849092 [TBL] [Abstract][Full Text] [Related]
2. HER2-targeted hybrid peptide that blocks HER2 tyrosine kinase disintegrates cancer cell membrane and inhibits tumor growth in vivo. Kawamoto M; Horibe T; Kohno M; Kawakami K Mol Cancer Ther; 2013 Apr; 12(4):384-93. PubMed ID: 23358664 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and toxicity of transferrin receptor-targeted hybrid peptide as a potent anticancer agent. Kawamoto M; Kohno M; Horibe T; Kawakami K Cancer Chemother Pharmacol; 2013 Mar; 71(3):799-807. PubMed ID: 23328867 [TBL] [Abstract][Full Text] [Related]
4. Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy. Yang L; Horibe T; Kohno M; Haramoto M; Ohara K; Puri RK; Kawakami K Mol Cancer Ther; 2012 Jan; 11(1):235-43. PubMed ID: 22084165 [TBL] [Abstract][Full Text] [Related]
5. Selective killing of cancer cells by peptide-targeted delivery of an anti-microbial peptide. Sioud M; Mobergslien A Biochem Pharmacol; 2012 Nov; 84(9):1123-32. PubMed ID: 22922046 [TBL] [Abstract][Full Text] [Related]
6. A novel interleukin-13 receptor alpha 2-targeted hybrid peptide for effective glioblastoma therapy. Kurihara R; Horibe T; Shimizu E; Torisawa A; Gaowa A; Kohno M; Kawakami K Chem Biol Drug Des; 2019 Jul; 94(1):1402-1413. PubMed ID: 30903640 [TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of antimicrobial peptides containing CisoDGRC in CD13 negative breast cancer cells. Hou L; Zhao X; Wang P; Ning Q; Meng M; Liu C PLoS One; 2013; 8(1):e53491. PubMed ID: 23326440 [TBL] [Abstract][Full Text] [Related]
8. Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate. Li S; Zhao H; Mao X; Fan Y; Liang X; Wang R; Xiao L; Wang J; Liu Q; Zhao G Pharm Res; 2019 Oct; 36(12):168. PubMed ID: 31654226 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene. Yang DC; Jiang XP; Elliott RL; Head JF Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259 [TBL] [Abstract][Full Text] [Related]
10. The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor. Qing Y; Shuo W; Zhihua W; Huifen Z; Ping L; Lijiang L; Xiaorong Z; Liming C; Daiwen X; Yu H; Wei X; Min F; Zuohua F; Guanxin S Cancer Immunol Immunother; 2006 Sep; 55(9):1111-21. PubMed ID: 16341531 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma. Seto K; Shoda J; Horibe T; Warabi E; Ishige K; Yamagata K; Kohno M; Yanagawa T; Bukawa H; Kawakami K Oncol Rep; 2013 Jun; 29(6):2147-53. PubMed ID: 23563734 [TBL] [Abstract][Full Text] [Related]
12. In vitro and initial in vivo evaluation of (68)Ga-labeled transferrin receptor (TfR) binding peptides as potential carriers for enhanced drug transport into TfR expressing cells. Wängler C; Nada D; Höfner G; Maschauer S; Wängler B; Schneider S; Schirrmacher E; Wanner KT; Schirrmacher R; Prante O Mol Imaging Biol; 2011 Apr; 13(2):332-41. PubMed ID: 20473573 [TBL] [Abstract][Full Text] [Related]
13. Immunotoxin sensitivity of Chinese hamster ovary cells expressing human transferrin receptors with differing internalization rates. Recht LD; Raso V; Davis R; Salmonsen R Cancer Immunol Immunother; 1996 Jul; 42(6):357-61. PubMed ID: 8830739 [TBL] [Abstract][Full Text] [Related]
14. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Leuschner C; Enright FM; Gawronska B; Hansel W Breast Cancer Res Treat; 2003 Mar; 78(1):17-27. PubMed ID: 12611453 [TBL] [Abstract][Full Text] [Related]
15. Uptake of 111In-labeled fully human monoclonal antibody TSP-A18 reflects transferrin receptor expression in normal organs and tissues of mice. Sugyo A; Tsuji AB; Sudo H; Nomura F; Satoh H; Koizumi M; Kurosawa G; Kurosawa Y; Saga T Oncol Rep; 2017 Mar; 37(3):1529-1536. PubMed ID: 28184946 [TBL] [Abstract][Full Text] [Related]
16. Characterization of antilytic peptide antibody: application for the detection of lytic-based hybrid peptide in serum samples. Ohara K; Horibe T; Kohno M; Kawakami K J Pept Sci; 2011 Jul; 17(7):493-8. PubMed ID: 21351323 [TBL] [Abstract][Full Text] [Related]
17. Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin. Shinohara H; Fan D; Ozawa S; Yano S; Van Arsdell M; Viner JL; Beers R; Pastan I; Fidler IJ Int J Oncol; 2000 Oct; 17(4):643-51. PubMed ID: 10995873 [TBL] [Abstract][Full Text] [Related]
18. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Daniels TR; Delgado T; Rodriguez JA; Helguera G; Penichet ML Clin Immunol; 2006 Nov; 121(2):144-58. PubMed ID: 16904380 [TBL] [Abstract][Full Text] [Related]
19. A novel hybrid peptide targeting EGFR-expressing cancers. Kohno M; Horibe T; Haramoto M; Yano Y; Ohara K; Nakajima O; Matsuzaki K; Kawakami K Eur J Cancer; 2011 Mar; 47(5):773-83. PubMed ID: 21112771 [TBL] [Abstract][Full Text] [Related]
20. Viral specific cytotoxic T cells inhibit the growth of TfR-expressing tumor cells with antibody targeted viral peptide/HLA-A2 complex. Li J; Weng X; Liang Z; Zhong M; Chen X; Lu S; Sun W; Song Y; Wu X; Shen G Cell Immunol; 2010; 263(2):154-60. PubMed ID: 20406704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]